{"id":"W2952953974","doi":"10.1016/j.jtho.2019.06.010","title":"Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Foundation Medicine; EMD Serono; Eisai; Daiichi-Sankyo; Pfizer; Incyte; Genentech; IFM Therapeutics; Horizon Pharma; Exelixis; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Roche; Celgene; Novartis; AbbVie; MedImmune; Merck; Boehringer Ingelheim; Amgen; PharmaMar; Daiichi Sankyo Europe; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Common Terminology Criteria for Adverse Events; Tolerability; Adverse effect; Internal medicine; Oncology; Cohort; Cancer; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001477195,0.0002622423,0.0007444215,0.0001844781,0.0002389551,0.0004263367,0.0002372205,0.0002834974,0.0006083632],"category_scores_gemma":[0.001552808,0.0001038659,0.0004731942,0.0002382555,0.00018136,0.0003236382,0.0001527322,0.0005898566,0.0001778389],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005402286,"about_ca_system_score_gemma":0.0003021726,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005887187,"about_ca_topic_score_gemma":0.001058558,"domain_scores_codex":[0.9995705,0.0001505984,0.00005025762,0.00006905055,0.0001086717,0.00005080283],"domain_scores_gemma":[0.9991059,0.0002582567,0.0003080242,0.0000408725,0.00009805281,0.0001890077],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0678167,0.002184381,0.7285576,0.0003995458,0.001483516,0.0009826553,0.0002828016,0.001997326,0.02217649,0.00007679353,0.001885193,0.172157],"study_design_scores_gemma":[0.004102075,0.04833963,0.9360526,0.00006159728,0.0009461803,0.001777353,0.00008383297,0.001862339,0.00359873,0.0001212976,0.0030279,0.00002654755],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956994,0.003115954,0.0001460467,0.00009564302,0.00001347537,0.00003570777,0.0002277468,0.00001001501,0.0006560578],"genre_scores_gemma":[0.9986355,0.0004225378,0.00009653164,0.00009809351,0.00002562365,0.00002584059,0.0004956585,0.000001740493,0.0001985205],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001477195,"threshold_uncertainty_score":0.007812262,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02307603620406029,"score_gpt":0.4132323152498739,"score_spread":0.3901562790458136,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}